Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis

被引：51

作者：

Smolen, JS

Breedveld, FC

Burmester, GR

Combe, B

Emery, P

Kalden, JR

Klareskog, L

Maini, RN

Numo, R

van de Putte, LBA

van Riel, PLCM

Rodriguez-Valverde, V

机构：

[1] Univ Cantabria, E-39005 Santander, Spain

[2] Univ Nijmegen, Nijmegen, Netherlands

[3] Univ Bari, I-70121 Bari, Italy

[4] Univ Charing Cross, London, England

[5] Univ Stockholm, S-10691 Stockholm, Sweden

[6] Univ Erlangen Nurnberg, D-8520 Erlangen, Germany

[7] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England

[8] Univ Montpellier, F-34059 Montpellier, France

[9] Leiden Univ, NL-2300 RA Leiden, Netherlands

[10] Univ Charite, Berlin, Germany

[11] Univ Vienna, Vienna Gen Hosp, Dept Internal Med 3, A-1090 Vienna, Austria

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2000年 / 59卷 / 07期

关键词：

D O I：

10.1136/ard.59.7.504

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：504 / 505

页数：2

共 16 条

[1] RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS [J].

ELLIOTT, MJ ;

MAINI, RN ;

FELDMANN, M ;

KALDEN, JR ;

ANTONI, C ;

SMOLEN, JS ;

LEEB, B ;

BREEDVELD, FC ;

MACFARLANE, JD ;

BIJL, H ;

WOODY, JN .

LANCET, 1994, 344 (8930) :1105-1110

[2] REPEATED THERAPY WITH MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) IN PATIENTS WITH RHEUMATOID-ARTHRITIS [J].

ELLIOTT, MJ ;

MAINI, RN ;

FELDMANN, M ;

LONGFOX, A ;

CHARLES, P ;

BIJL, H ;

WOODY, JN .

LANCET, 1994, 344 (8930) :1125-1127

[3] USE OF SHORT-TERM EFFICACY TOXICITY TRADEOFFS TO SELECT 2ND-LINE DRUGS IN RHEUMATOID-ARTHRITIS - A METAANALYSIS OF PUBLISHED CLINICAL-TRIALS [J].

FELSON, DT ;

ANDERSON, JJ ;

MEENAN, RF .

ARTHRITIS AND RHEUMATISM, 1992, 35 (10) :1117-1125

[4] AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY DEFINITION OF IMPROVEMENT IN RHEUMATOID-ARTHRITIS [J].

FELSON, DT ;

ANDERSON, JJ ;

BOERS, M ;

BOMBARDIER, C ;

FURST, D ;

GOLDSMITH, C ;

KATZ, LM ;

LIGHTFOOT, R ;

PAULUS, H ;

STRAND, V ;

TUGWELL, P ;

WEINBLATT, M ;

WILLIAMS, HJ ;

WOLFE, F ;

KIESZAK, S .

ARTHRITIS AND RHEUMATISM, 1995, 38 (06) :727-735

[5]

Finck B, 1999, ARTHRITIS RHEUM, V42, pS117

[6]

Furst DE, 1999, ANN RHEUM DIS, V58, P129

[7]

Lipsky P, 1999, ARTHRITIS RHEUM, V42, pS401

[8] Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial [J].

Maini, R ;

St Clair, EW ;

Breedveld, F ;

Furst, D ;

Kalden, J ;

Weisman, M ;

Smolen, J ;

Emery, P ;

Harriman, G ;

Feldmann, M ;

Lipsky, P .

LANCET, 1999, 354 (9194) :1932-1939

[9]

Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO

[10]

2-W

← 1 2 →